DelveInsight’s “Adrenocortical Carcinoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Adrenocortical Carcinoma, historical and forecasted epidemiology as well as the Adrenocortical Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Adrenocortical Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adrenocortical Carcinoma Market Forecast
Some of the key facts of the Adrenocortical Carcinoma Market Report:
The Adrenocortical Carcinoma market size was valued ~USD 23 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In April 2025, Cytovation ASA, a clinical-stage oncology firm developing the first-in-class bifunctional peptide CY-101, has secured NOK 62 million (approximately USD 6 million) in funding, primarily from existing investors, with Sandwater leading the round. The proceeds will support the progression of CY-101 into a multinational Phase 2 clinical trial for patients with adrenocortical carcinoma, scheduled to commence in late 2025, with initial clinical data anticipated in 2026.
In January 2025, Cancer Research UK, Cytovation, and the Norwegian Cancer Society entered into a collaboration to advance Cytovation’s lead candidate, CY-101, into a multinational Phase 2 clinical trial targeting adrenocortical carcinoma (ACC). CY-101 is a synthetic peptide with dual-action capabilities: it selectively eliminates cancer cells while initiating a systemic immune response and concurrently blocks the Wnt/β-catenin signaling pathway—a major contributor to immunotherapy resistance in cancers like ACC.
In 2023, the United States had the largest number of new Adrenocortical Carcinoma cases among Western nations, making up nearly 27% of the total cases in the 7MM. The combined total for the EU4 and the UK represented about 53% of the cases in the 7MM, while Japan accounted for just 20% of the overall cases.
According to DelveInsight’s assessment in 2023, there were 1,245 new cases of Adrenocortical Carcinoma (ACC) in the 7MM. These cases are expected to see an upward trend with a projected CAGR during the forecast period from 2024 to 2034.
In 2023, 40% of males and 60% of females in the 7MM had Adrenocortical Carcinoma (ACC). This indicates a lower incidence of ACC in males compared to females.
In 2023, EU4 and the UK reported 658 incident cases of Adrenocortical Carcinoma. These numbers are anticipated to rise in the coming years due to improved diagnostic capabilities and heightened disease awareness.
In 2023, Japan recorded 247 incident cases of Adrenocortical Carcinoma. DelveInsight projects that by 2034, the total number of cases in Japan is expected to decline due to the decreasing population and other factors.
According to DelveInsight’s analysis, incident cases of Adrenocortical Carcinoma were categorized into four age groups: 60 years. In the 7MM in 2023, the highest number of cases occurred in the 41–60 years age group, followed by those aged >60 years, 20–40 years, and
Key Adrenocortical Carcinoma Companies: Enterome/Bristol-Myers Squibb, UNICANCER, Fusion Pharmaceuticals, and others
Key Adrenocortical Carcinoma Therapies: EO2401 + Nivolumab, Dostarlimab, [111In]-FPI-1547 Injection, and others
The Adrenocortical Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Adrenocortical Carcinoma pipeline products will significantly revolutionize the Adrenocortical Carcinoma market dynamics.
Adrenocortical Carcinoma Overview
Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that originates in the cortex (outer layer) of the adrenal glands. These glands, located on top of each kidney, produce hormones such as cortisol, aldosterone, and androgens, which are vital for various bodily functions.
Get a Free sample for the Adrenocortical Carcinoma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market
Adrenocortical Carcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Adrenocortical Carcinoma Epidemiology Segmentation:
The Adrenocortical Carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Adrenocortical Carcinoma
Prevalent Cases of Adrenocortical Carcinoma by severity
Gender-specific Prevalence of Adrenocortical Carcinoma
Diagnosed Cases of Episodic and Chronic Adrenocortical Carcinoma
Download the report to understand which factors are driving Adrenocortical Carcinoma epidemiology trends @ Adrenocortical Carcinoma Epidemiology Forecast
Adrenocortical Carcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adrenocortical Carcinoma market or expected to get launched during the study period. The analysis covers Adrenocortical Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Adrenocortical Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Adrenocortical Carcinoma Therapies and Key Companies
EO2401 + Nivolumab : Enterome/Bristol-Myers Squibb
Dostarlimab: UNICANCER
[111In]-FPI-1547 Injection: Fusion Pharmaceuticals
Discover more about therapies set to grab major Adrenocortical Carcinoma market share @ Adrenocortical Carcinoma Treatment Landscape
Adrenocortical Carcinoma Market Strengths
The availability of surgical interventions like adrenalectomy offers a viable option for removing the affected adrenal gland, enhancing treatment accessibility.
The exclusive approval of Mitotane, listed as an ‘Off-Patent, Off-Exclusivity Drug without an Approved Generic’ in the Orange Book, consolidates its position as the primary therapeutic option for ACC.
Adrenocortical Carcinoma Market Opportunities
The opportunity lies in the potential of the EO2401 + Nivolumab combination to address immunotherapy resistance, a prevailing challenge in ACC treatment.
The therapeutic market of ACC is very scarce, creating an opportunity for key market players to enter the ACC market.
Scope of the Adrenocortical Carcinoma Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Adrenocortical Carcinoma Therapeutic Assessment: Adrenocortical Carcinoma current marketed and Adrenocortical Carcinoma emerging therapies
Adrenocortical Carcinoma Market Dynamics: Adrenocortical Carcinoma market drivers and Adrenocortical Carcinoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Adrenocortical Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Adrenocortical Carcinoma Market Access and Reimbursement
To know more about Adrenocortical Carcinoma companies working in the treatment market, visit @ Adrenocortical Carcinoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Adrenocortical Carcinoma Market Report Introduction
2. Executive Summary for Adrenocortical Carcinoma
3. SWOT analysis of Adrenocortical Carcinoma
4. Adrenocortical Carcinoma Patient Share (%) Overview at a Glance
5. Adrenocortical Carcinoma Market Overview at a Glance
6. Adrenocortical Carcinoma Disease Background and Overview
7. Adrenocortical Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Adrenocortical Carcinoma
9. Adrenocortical Carcinoma Current Treatment and Medical Practices
10. Adrenocortical Carcinoma Unmet Needs
11. Adrenocortical Carcinoma Emerging Therapies
12. Adrenocortical Carcinoma Market Outlook
13. Country-Wise Adrenocortical Carcinoma Market Analysis (2020–2034)
14. Adrenocortical Carcinoma Market Access and Reimbursement of Therapies
15. Adrenocortical Carcinoma Market Drivers
16. Adrenocortical Carcinoma Market Barriers
17. Adrenocortical Carcinoma Appendix
18. Adrenocortical Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
